Blood
Articles in this Issue
High-dose ponatinib in Korean CML and Ph+ ALL: real-world outcomes in early and heavily pretreated settings
Abstract Background: Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), has shown effectiveness and safety i...
Ruxolitinib may treat aplastic anaemia by reducing levels of macrophage pyroptosis
Abstract Abstract Background: Severe Aplastic anaemia (SAA) is a disorder of bone marrow haematopoiesis caused by a variety of aetiological...
Assessing the impact of an OSCE-style workshop on internal medicine residents' ability to manage hematologic emergencies: An iterative pilot study
Abstract Introduction We conducted a survey of Canadian Internal Medicine (IM) residents which identified significant ga...
A real-world Study of romiplostim and short-course prednisone as first-line therapy for elderly immune thrombocytopenia (≥60 Years)
Abstract Background Immune thrombocytopenia (ITP) is an autoimmune disorder caused by increased platelet destruction and suboptimal platelet...
DIPSS-R: A revised age-agnostic clinical risk model for chronic phase primary myelofibrosis
Abstract Background: The International Prognostic Scoring System (IPSS; Cervantes et al. Blood 2009;113) and dynamic IPSS (DIPSS; Passamonti...
Patterns of management and healthcare utilization in older adult patients with TP53-mutated AML and MDS: A retrospective analysis
Abstract Background: Optimal management of TP53-mutated acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS)...
Ruxolitinib mitigates interferon-induced autoimmune toxicity: Clinical insights from a 465-patient MPN Cohort Retrospective study
Abstract Background: Myeloproliferative neoplasms (MPNs) are characterized by intrinsic immune dysregulation, with a high incidence of autoi...
Fetal hemogenic endothelium-derived multipotent progenitors are early responders to prenatal inflammation and shape postnatal myeloid immunity
Abstract Accumulating evidence suggests that prenatal factors, such as maternal infection, diet, and obesity, are linked to increased risk o...
A population-based gap analysis of bispecific antibody trial access: Racial, geographic, and Medicaid-linked disparities in lymphoma and myeloma
Abstract Background: Bispecific antibodies (bsAbs), such as epcoritamab (CD3×CD20 for DLBCL; FDA-approved May 2023) and elranatamab (BCMA×CD...
ALK+ LBCL and PBL share a similar plasmablastic transcriptional identity but show divergent signaling dependencies and therapeutic vulnerabilities
Abstract Introduction: Plasmablastic lymphoma (PBL) and ALK-positive large B-cell lymphoma (ALK+ LBCL) are rare, aggressive lymphomas charac...
Beyond MRD: The importance of weight recovery in adults with ALL
Abstract Background: The treatment of acute lymphoblastic leukemia (ALL) in adults has improved with pediatric-inspired...
CAR-NK cell therapy in hematologic malignancies (2019–2025): A systematic review
Abstract Chimeric antigen receptor natural killer (CAR-NK) cell therapy has rapidly progressed in early-phase clinical trials for hematologi...
DYRK1A interacts with EZH2 to regulate transcriptionally active chromatin in myeloid leukemia associated with down syndrome
Abstract Children with Down syndrome are predisposed to hematological malignancies due to the presence of an extra copy of chromosome 21. Tr...
Super-enhancer-mediated regulation of CD38 inducibility in multiple myeloma via the MAF/TRIM47/RARα axis
Abstract Dysregulation of the MAF transcription factor, frequently overexpressed in multiple myeloma (MM) due to adverse translocations like...
In vitro and In Vivo FOXO3 dependent induction of fetal hemoglobin
Abstract Background: Induction of fetal hemoglobin (HbF) is a key therapeutic strategy to treat sickle cell disease (SCD). Unfortunately, th...
Azeliragon has significant activity against acute myeloid leukemia blasts
Abstract High Mobility Group Box-1 (HMGB1) is a non-histone chromosome binding protein that has a dual function. Intracellular HMGB1 binds t...
Fraternal but not identical twins: HLH and ICANS look a lot alike
Abstract CD19 CAR-T therapy has improved treatment for refractory/relapsed B-ALL, however, toxicities like cytokine release syndrome (CRS),...
Impact of prior BCMA-targeted therapy on CAR-T expansion and host T-cell phenotypes in patients with Relapsed/Refractory multiple myeloma receiving BCMA CAR-T therapy
Abstract Background: B-cell maturation antigen (BCMA)-targeted therapies such as chimeric antigen receptor T-cell (CAR-T) therapy and bispeci...
Mutant megakaryocytes orchestrate marrow immune remodeling via inflammatory and LINE‑1–Driven mechanisms in MPNs
Abstract Introduction Megakaryocytes (MKs), traditionally recognized as the precursors of platelets, have emerged as key regulators of the he...
Association between COMT activity and development of infections during therapy for pediatric acute lymphoblastic leukemia
Abstract Introduction: While modern therapy has led to high survival rates for acute lymphoblastic leukemia (ALL), treatment can lead to adv...
Early AKI and transfusion burden following venetoclax-based therapy in AML versus multiple myeloma: A retrospective real-world analysis
Abstract Venetoclax has become a critical component of frontline therapy in acute myeloid leukemia (AML) and an emerging option in selected...
Enhancing anticoagulation stewardship: A resident-focused quality improvement project
Abstract Background: Anticoagulation (AC) is a cornerstone in the management of hematologic and thromboembolic disorders...
CSF3R-mutated chronic neutrophilic leukemia: A two-center study of 44 consecutive patients
Abstract Introduction: CSF3R mutations (CSF3RMUT), most commonly T618I, represent the defining genomic alteration in chronic neutrophilic le...
Point of care hemoglobin measurement to streamline clinical decision-making: A single center experience
Abstract Introduction: Achieving appropriate transfusion and phlebotomy target is essential to the health and wellbeing of patients with con...
Sickle cell disease presenting with chronic lower extremity ulcers
Abstract Introduction Lower extremity ulcerations (LEU), usually caused by peripheral neuropathy, venous insufficiency, peripheral artery di...